About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT01234571

Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension

Remodulin (Treprostenil sodium) is synthetic prostacyclin analog available as a solution for administration in the intravenous route. It is approved for treatment of class I - pulmonary hypertension f...

Lead sponsor: Rambam Health Care Campus•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Rambam Health Care Campus

After giving informed consent 10 ml of blood will be drawn from the study population at the following occasions. * Baseline measurement immediately before starting HD therapy. * During the hemo-dialysis therapy - every one hour. * After the end of the hemo-dialysis therapy - every one hour (a total of four measurements) to record recovery of Treprostenil blood levels.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Exclusion Criteria

•none

Related studies

Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure

NCT07656168 · ESRD (End-Stage Renal Disease), Maintenance Hemodialysis

RECRUITINGPhase 1

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

NCT07348237 · Chronic Kidney Failure, End-Stage Renal Disease, and more

RECRUITINGPhase 2

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183 · Pulmonary Hypertension, Interstitial Lung Disease (ILD), and more

RECRUITINGPhase 1/2

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039 · Obesity, Interstitial Lung Disease, and more

Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.

NCT07537517 · Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 4, 2010Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment5

Start dateNov 2010

Last updatedNov 4, 2010

Condition

Pulmonary Hypertension End-Stage Renal Disease Hemo-dialysis Therapy

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2010Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions